DK3229776T3 - Farmaceutisk sammensætning, der kombinerer mindst to særskilte nanopartikler og en farmaceutisk forbindelse, fremstilling og anvendelser deraf - Google Patents

Farmaceutisk sammensætning, der kombinerer mindst to særskilte nanopartikler og en farmaceutisk forbindelse, fremstilling og anvendelser deraf Download PDF

Info

Publication number
DK3229776T3
DK3229776T3 DK15800777.3T DK15800777T DK3229776T3 DK 3229776 T3 DK3229776 T3 DK 3229776T3 DK 15800777 T DK15800777 T DK 15800777T DK 3229776 T3 DK3229776 T3 DK 3229776T3
Authority
DK
Denmark
Prior art keywords
preparation
pharmaceutical
pharmaceutical composition
composition combining
distinct nanoparticles
Prior art date
Application number
DK15800777.3T
Other languages
Danish (da)
English (en)
Inventor
Agnès Pottier
Laurent Levy
Matthieu Germain
Marie-Edith Meyre
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Application granted granted Critical
Publication of DK3229776T3 publication Critical patent/DK3229776T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK15800777.3T 2014-11-25 2015-11-24 Farmaceutisk sammensætning, der kombinerer mindst to særskilte nanopartikler og en farmaceutisk forbindelse, fremstilling og anvendelser deraf DK3229776T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306874 2014-11-25
PCT/EP2015/077446 WO2016083343A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof

Publications (1)

Publication Number Publication Date
DK3229776T3 true DK3229776T3 (da) 2023-07-31

Family

ID=52013981

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15800777.3T DK3229776T3 (da) 2014-11-25 2015-11-24 Farmaceutisk sammensætning, der kombinerer mindst to særskilte nanopartikler og en farmaceutisk forbindelse, fremstilling og anvendelser deraf

Country Status (13)

Country Link
US (2) US10391058B2 (enExample)
EP (1) EP3229776B1 (enExample)
JP (1) JP6836510B2 (enExample)
AR (1) AR102781A1 (enExample)
DK (1) DK3229776T3 (enExample)
ES (1) ES2951598T3 (enExample)
FI (1) FI3229776T3 (enExample)
HU (1) HUE062561T2 (enExample)
LT (1) LT3229776T (enExample)
PL (1) PL3229776T3 (enExample)
PT (1) PT3229776T (enExample)
TW (1) TW201628654A (enExample)
WO (1) WO2016083343A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015029853A2 (pt) 2013-05-30 2017-07-25 Nanobiotix uso de uma composição farmacêutica
PT3229776T (pt) * 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
JP6789960B2 (ja) 2014-11-25 2020-11-25 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製及び使用
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
LT3223796T (lt) 2014-11-25 2021-10-25 Curadigm Sas Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai
EA201792560A1 (ru) 2015-05-28 2018-06-29 Нанобиотикс Наночастицы для применения в качестве терапевтической вакцины
CN115137822B (zh) * 2022-06-13 2023-06-23 武汉大学中南医院 一种光热热电一体化的抗肿瘤植入体的制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
WO1998017667A1 (en) 1996-10-18 1998-04-30 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
DK1007034T3 (da) 1997-08-19 2004-03-22 Warner Lambert Co Præparater indeholdende Bergamottin til forøgelse af den orale biotilgængelighed af farmaceutiske midler
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AU7038501A (en) * 2000-06-30 2002-01-14 Inex Pharmaceuticals Corp Liposomal antineoplastic drugs and uses thereof
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
AU2004308756B2 (en) 2003-12-22 2010-06-24 Bracco Suisse S.A. Gas-filled microvesicle assembly for contrast imaging
US20080193372A1 (en) * 2004-02-10 2008-08-14 Barnes-Jewish Hospital Efficacy and Safety of Targeted Particulate Agents with Decoy Systems
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
US20070088414A1 (en) * 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) * 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
WO2007116954A2 (en) 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
US20090181076A1 (en) 2006-05-04 2009-07-16 University Of South Australia Drug Release From Nanoparticle-Coated Capsules
EA201070296A1 (ru) 2007-08-21 2010-08-30 Алза Корпорейшн Липосомные композиции для введения in vivo соединений бороновой кислоты
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2231765A2 (en) 2007-12-21 2010-09-29 University Of Guelph Polysaccharide nanoparticles
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
CN102781472B (zh) 2010-02-17 2014-07-02 国立大学法人神户大学 放射线治疗剂
HRP20160609T1 (hr) 2010-03-26 2016-09-23 Abraxis Bioscience, Llc Postupci liječenja hepatocelularnog karcinoma
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
KR20130132475A (ko) 2010-12-17 2013-12-04 애로우헤드 리서치 코오포레이션 ｓｉＲＮＡ의 갈락토오스 클러스터-약동학적 조절제 표적 물질
CN103429227B (zh) * 2011-01-31 2017-12-19 纳米生物技术公司 纳米粒子递送系统、其制备及应用
US20140227343A1 (en) * 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
US10251841B2 (en) 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
BR112015029853A2 (pt) 2013-05-30 2017-07-25 Nanobiotix uso de uma composição farmacêutica
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
PT3229776T (pt) * 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
CA2968473A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
JP6789960B2 (ja) 2014-11-25 2020-11-25 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製及び使用
LT3223796T (lt) 2014-11-25 2021-10-25 Curadigm Sas Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai

Also Published As

Publication number Publication date
US20190374465A1 (en) 2019-12-12
FI3229776T3 (fi) 2023-08-15
JP6836510B2 (ja) 2021-03-03
LT3229776T (lt) 2023-08-25
PT3229776T (pt) 2023-08-17
EP3229776A1 (en) 2017-10-18
WO2016083343A1 (en) 2016-06-02
TW201628654A (zh) 2016-08-16
ES2951598T3 (es) 2023-10-23
US10391058B2 (en) 2019-08-27
HUE062561T2 (hu) 2023-11-28
EP3229776B1 (en) 2023-06-28
JP2018504450A (ja) 2018-02-15
US20170258717A1 (en) 2017-09-14
AR102781A1 (es) 2017-03-22
US11471410B2 (en) 2022-10-18
PL3229776T3 (pl) 2023-11-06

Similar Documents

Publication Publication Date Title
SI3297605T1 (sl) Topikalni farmacevtski sestavki
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
IL243608A0 (en) Substances with antiviral activity, preparations containing them and their uses
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib
DK3229776T3 (da) Farmaceutisk sammensætning, der kombinerer mindst to særskilte nanopartikler og en farmaceutisk forbindelse, fremstilling og anvendelser deraf
IL290114A (en) Pharmaceutical preparations, their preparation and uses
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
PL3207149T3 (pl) Kompozycja farmaceutyczna o zwiększonej stabilności
DK3275452T3 (da) Farmaceutisk sammensætning med silibinin
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
LT3256154T (lt) Farmacinė kompozicija, apimanti antikūną
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
LT3389633T (lt) Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį
BR112016030507A2 (pt) Compostos relacionados à vitamina d, composição farmacêutica, e kit
IL239874B (en) History of acylguanidine, their preparation and pharmaceutical preparations containing them
DK3089740T3 (da) Farmaceutisk sammensætning
DK2915526T3 (da) Farmaceutiske sammensætninger, der omfatter anagrelid
DK3424500T3 (da) Farmaceutisk sammensætning, der omfatter famitinib
LT3377044T (lt) Ibuprofeno kompozicijos, skirtos tiesioginiam peroraliniam įvedimui
TH1501007100A (th) องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน
HUE063849T2 (hu) Tömörített gyógyszerészeti készítmény
BR112017004882A2 (pt) composição farmacêutica oral.
TH1401004645B (th) องค์ประกอบทางเภสัชกรรมที่สามารถให้ได้โดยการรับประทาน